Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 1.97
REGN's Cash to Debt is ranked higher than
59% of the 1443 Companies
in the Global Biotechnology industry.

( Industry Median: 51.73 vs. REGN: 1.97 )
REGN' s 10-Year Cash to Debt Range
Min: 0.67   Max: No Debt
Current: 1.97

Equity to Asset 0.66
REGN's Equity to Asset is ranked higher than
72% of the 1090 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. REGN: 0.66 )
REGN' s 10-Year Equity to Asset Range
Min: 0.27   Max: 0.87
Current: 0.66

0.27
0.87
Interest Coverage 22.43
REGN's Interest Coverage is ranked higher than
50% of the 654 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. REGN: 22.43 )
REGN' s 10-Year Interest Coverage Range
Min: 0.46   Max: 22.43
Current: 22.43

0.46
22.43
F-Score: 5
Z-Score: 23.87
M-Score: -2.94
WACC vs ROIC
6.23%
18.66%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 29.74
REGN's Operating margin (%) is ranked higher than
96% of the 1168 Companies
in the Global Biotechnology industry.

( Industry Median: -95.34 vs. REGN: 29.74 )
REGN' s 10-Year Operating margin (%) Range
Min: -554.63   Max: 187.97
Current: 29.74

-554.63
187.97
Net-margin (%) 12.34
REGN's Net-margin (%) is ranked higher than
90% of the 1168 Companies
in the Global Biotechnology industry.

( Industry Median: -77.05 vs. REGN: 12.34 )
REGN' s 10-Year Net-margin (%) Range
Min: -565.66   Max: 54.43
Current: 12.34

-565.66
54.43
ROE (%) 14.97
REGN's ROE (%) is ranked higher than
93% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: -31.17 vs. REGN: 14.97 )
REGN' s 10-Year ROE (%) Range
Min: -75.77   Max: 86.68
Current: 14.97

-75.77
86.68
ROA (%) 10.07
REGN's ROA (%) is ranked higher than
94% of the 1451 Companies
in the Global Biotechnology industry.

( Industry Median: -25.65 vs. REGN: 10.07 )
REGN' s 10-Year ROA (%) Range
Min: -28.05   Max: 44.08
Current: 10.07

-28.05
44.08
ROC (Joel Greenblatt) (%) 56.16
REGN's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 1411 Companies
in the Global Biotechnology industry.

( Industry Median: -346.25 vs. REGN: 56.16 )
REGN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -214.91   Max: 168.03
Current: 56.16

-214.91
168.03
Revenue Growth (3Y)(%) 71.60
REGN's Revenue Growth (3Y)(%) is ranked higher than
97% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. REGN: 71.60 )
REGN' s 10-Year Revenue Growth (3Y)(%) Range
Min: -25.3   Max: 81.3
Current: 71.6

-25.3
81.3
» REGN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

REGN Guru Trades in Q1 2014

Ron Baron 6,084 sh (New)
Andreas Halvorsen 1,051,800 sh (New)
Paul Tudor Jones 893 sh (New)
Steven Cohen 65,232 sh (+130.47%)
Vanguard Health Care Fund 1,743,468 sh (+23.47%)
Frank Sands 4,012,062 sh (+7.48%)
Jim Simons Sold Out
» More
Q2 2014

REGN Guru Trades in Q2 2014

Jim Simons 2,862 sh (New)
Ray Dalio 18,400 sh (New)
Mario Gabelli 2,295 sh (New)
Joel Greenblatt 881 sh (New)
Andreas Halvorsen 2,963,456 sh (+181.75%)
Vanguard Health Care Fund 2,795,500 sh (+60.34%)
Frank Sands 4,907,362 sh (+22.32%)
Ron Baron 7,109 sh (+16.85%)
Steven Cohen 14,500 sh (unchged)
Paul Tudor Jones Sold Out
» More
Q3 2014

REGN Guru Trades in Q3 2014

Paul Tudor Jones 2,499 sh (New)
Ken Fisher 583 sh (New)
Jim Simons 26,562 sh (+828.09%)
Steven Cohen 23,600 sh (+62.76%)
Joel Greenblatt 1,410 sh (+60.05%)
Frank Sands 4,967,466 sh (+1.22%)
Vanguard Health Care Fund 2,795,500 sh (unchged)
Ron Baron 7,109 sh (unchged)
Mario Gabelli 2,190 sh (-4.58%)
Andreas Halvorsen 1,080,682 sh (-63.53%)
Ray Dalio 1,600 sh (-91.30%)
» More
Q4 2014

REGN Guru Trades in Q4 2014

Ray Dalio 11,800 sh (+637.50%)
Ron Baron 7,490 sh (+5.36%)
Vanguard Health Care Fund 2,921,000 sh (+4.49%)
Frank Sands 4,986,177 sh (+0.38%)
Frank Sands 4,986,177 sh (+0.38%)
Mario Gabelli 2,190 sh (unchged)
Steven Cohen Sold Out
Jim Simons Sold Out
Andreas Halvorsen Sold Out
Paul Tudor Jones Sold Out
Joel Greenblatt Sold Out
Ken Fisher 524 sh (-10.12%)
» More
» Details

Insider Trades

Latest Guru Trades with REGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 157.00
REGN's P/E(ttm) is ranked higher than
87% of the 1611 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. REGN: 157.00 )
REGN' s 10-Year P/E(ttm) Range
Min: 9.83   Max: 159.45
Current: 157

9.83
159.45
Forward P/E 39.53
REGN's Forward P/E is ranked higher than
91% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. REGN: 39.53 )
N/A
PE(NRI) 155.00
REGN's PE(NRI) is ranked higher than
89% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. REGN: 155.00 )
REGN' s 10-Year PE(NRI) Range
Min: 10.65   Max: 160.29
Current: 155

10.65
160.29
P/B 19.20
REGN's P/B is ranked lower than
58% of the 1612 Companies
in the Global Biotechnology industry.

( Industry Median: 7.01 vs. REGN: 19.20 )
REGN' s 10-Year P/B Range
Min: 1.43   Max: 26.42
Current: 19.2

1.43
26.42
P/S 19.40
REGN's P/S is ranked higher than
68% of the 1611 Companies
in the Global Biotechnology industry.

( Industry Median: 37.64 vs. REGN: 19.40 )
REGN' s 10-Year P/S Range
Min: 2.06   Max: 27.97
Current: 19.4

2.06
27.97
PFCF 133.90
REGN's PFCF is ranked higher than
89% of the 1611 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. REGN: 133.90 )
REGN' s 10-Year PFCF Range
Min: 9.29   Max: 2102
Current: 133.9

9.29
2102
POCF 72.60
REGN's POCF is ranked higher than
91% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. REGN: 72.60 )
REGN' s 10-Year POCF Range
Min: 7.52   Max: 359.87
Current: 72.6

7.52
359.87
EV-to-EBIT 57.32
REGN's EV-to-EBIT is ranked higher than
92% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. REGN: 57.32 )
REGN' s 10-Year EV-to-EBIT Range
Min: -106.3   Max: 2827.2
Current: 57.32

-106.3
2827.2
Shiller P/E 346.00
REGN's Shiller P/E is ranked higher than
91% of the 1611 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. REGN: 346.00 )
REGN' s 10-Year Shiller P/E Range
Min: 271.85   Max: 1374.3
Current: 346

271.85
1374.3
Current Ratio 3.31
REGN's Current Ratio is ranked higher than
68% of the 1406 Companies
in the Global Biotechnology industry.

( Industry Median: 4.39 vs. REGN: 3.31 )
REGN' s 10-Year Current Ratio Range
Min: 2.81   Max: 17.9
Current: 3.31

2.81
17.9
Quick Ratio 3.11
REGN's Quick Ratio is ranked higher than
68% of the 1406 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. REGN: 3.11 )
REGN' s 10-Year Quick Ratio Range
Min: 2.81   Max: 17.72
Current: 3.11

2.81
17.72
Days Inventory 183.72
REGN's Days Inventory is ranked higher than
82% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. REGN: 183.72 )
REGN' s 10-Year Days Inventory Range
Min: 61.88   Max: 432.93
Current: 183.72

61.88
432.93
Days Sales Outstanding 95.71
REGN's Days Sales Outstanding is ranked higher than
76% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 139.31 vs. REGN: 95.71 )
REGN' s 10-Year Days Sales Outstanding Range
Min: 6.35   Max: 201.38
Current: 95.71

6.35
201.38

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 259.50
REGN's Price/Net Current Asset Value is ranked higher than
65% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 28.14 vs. REGN: 259.50 )
REGN' s 10-Year Price/Net Current Asset Value Range
Min: 3.4   Max: 50.15
Current: 259.5

3.4
50.15
Price/Tangible Book 19.20
REGN's Price/Tangible Book is ranked higher than
59% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 10.50 vs. REGN: 19.20 )
REGN' s 10-Year Price/Tangible Book Range
Min: 1.73   Max: 16.53
Current: 19.2

1.73
16.53
Price/DCF (Projected) 19.00
REGN's Price/DCF (Projected) is ranked higher than
93% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. REGN: 19.00 )
REGN' s 10-Year Price/DCF (Projected) Range
Min: 16.2   Max: 24.91
Current: 19

16.2
24.91
Price/Median PS Value 1.80
REGN's Price/Median PS Value is ranked higher than
78% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. REGN: 1.80 )
REGN' s 10-Year Price/Median PS Value Range
Min: 0.28   Max: 4.78
Current: 1.8

0.28
4.78
Price/Graham Number 11.00
REGN's Price/Graham Number is ranked higher than
90% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. REGN: 11.00 )
REGN' s 10-Year Price/Graham Number Range
Min: 1.24   Max: 9.42
Current: 11

1.24
9.42
Earnings Yield (Greenblatt) 1.70
REGN's Earnings Yield (Greenblatt) is ranked higher than
89% of the 1398 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. REGN: 1.70 )
REGN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.3   Max: 24.9
Current: 1.7

1.3
24.9

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:REGN.Switzerland,
Regeneron Pharmaceuticals Inc was incorporated in in the State of New York on January 1988. The Company is a biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. The Company's preclinical research programs are in the areas of oncology and angiogenesis, ophthalmology, metabolic and related diseases, muscle diseases and disorders, inflammation and immune diseases, bone and cartilage, pain, cardiovascular diseases, and infectious diseases. Its manufacturing facilities are located in Rensselaer, New York and consist of three buildings totaling approximately 490,000 square feet of research, manufacturing, office, and warehouse space. It currently has approximately 74,000liters of cell culture capacity at these facilities. It faces competition from pharmaceutical, biotechnology, and chemical companies. Its competitors are Genentech, Novartis, Pfizer Inc., Bayer HealthCare, Onyx Pharmaceuticals, Inc., Eli Lilly and Company, Abbott, sanofi-aventis, Merck & Co., Amgen Inc., Roche, and others. Its present and future business would be subject to regulation under the United States Atomic Energy Act, the Clean Air Act, the Clean Water Act, the Comprehensive Environmental Response, Compensation and Liability Act, the National Environmental Policy Act, the Toxic Substances Control Act, the Resource Conservation and Recovery Act, national restrictions, and other current and potential future local, state, federal, and foreign regulations.
» More Articles for REGN

Headlines

Articles On GuruFocus.com
Brean Capital Weighs in on Medivation Following Update on TERRAIN Study Mar 26 2015 
1 Feb 23 2015 
1 Feb 23 2015 
Can These Three BioTech Companies Make It Big? Feb 20 2015 
J.P. Morgan Chimes In With Ratings On BioTech Stocks Jan 06 2015 
Weekly Insider Sells Highlight: REGN, HSP, TYC, AAPL Nov 30 2014 
S&P 500 Finishes Above 2,000 Aug 27 2014 
How Sanofi's Growth Strategy Will Catapult Afrezza Into a Blockbuster Drug Aug 20 2014 
Weekly Insider Sells Highlight: MSFT, REGN, ATVI, MAA Feb 17 2014 
Insiders Are Buying Ophthotech Oct 08 2013 

More From Our Partners
Stock Market News for April 09, 2015 - Market News Apr 9 2015 - ZACKS

More From Other Websites
Jim Cramer Loves Regeneron, Sees Shares Headed to $500 Apr 24 2015
Cramer's Stop Trading: Regeneron gets to $500 Apr 24 2015
U.S. benchmarks chip away at major resistance Apr 23 2015
Amgen: But What About the Biosimilars? Apr 22 2015
Regeneron Bounces Higher Off Support Apr 22 2015
Amgen tops estimates with 51 percent spike in 1Q profit Apr 21 2015
Amgen tops estimates with 51 percent spike in 1Q profit Apr 21 2015
BioMed Realty, L.P. -- Moody's upgrades BioMed's senior unsecured ratings to Baa2; outlook is stable Apr 20 2015
Cuomo's headed for Cuba, but don't expect a 'Nixon goes to China' moment Apr 20 2015
Cuba Mission by Cuomo May Boost Democrats in Swing-State Florida Apr 19 2015
How Marketing And Media Muddled The Truth About The Heart Drug Vytorin Apr 16 2015
Regeneron CEO Joins Cuba Trade Trip With New York Governor Cuomo Apr 15 2015
Another bad year for stockpickers? Goldman Sachs thinks so Apr 14 2015
Regeneron to Report First Quarter 2015 Financial and Operating Results and Host Conference Call and... Apr 10 2015
Regeneron to Report First Quarter 2015 Financial and Operating Results and Host Conference Call and... Apr 10 2015
Cramer: How to play the Apple downgrade Apr 08 2015
Stock Market News for April 08, 2015 - Market News Apr 08 2015
Sanofi and Regeneron Announce 18-Month Results of ODYSSEY LONG TERM Trial with Praluent(TM)... Apr 07 2015
FedEx gains on TNT deal; GM slides as Canada unwinds stake Apr 07 2015
Don't Miss Your Chance To Buy This High-Ranking Biotech On Sale Apr 03 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK